Core Insights - NurExone Biologic Inc. announced that its exosomes outperformed a recognized commercial industry standard in key healing tasks such as nerve repair, wound repair, immune system modulation, and tissue rebuilding, indicating broad potential in therapeutic and aesthetic markets [1][6] Group 1: Exosome Performance - Independent study results showed NurExone's exosomes exhibit approximately 1.8-fold higher neurological potential, nearly double the anti-inflammatory activity, and a two-fold increase in tissue-regeneration and wound-healing signals compared to commercial benchmarks [4] - The exosomes produced by NurExone's U.S. subsidiary, ExoTOP Inc., are expected to deliver more than twice the wound-healing signals than the industry benchmark, suggesting applications in aesthetic skin rejuvenation, wound care, and orthopedic tissue repair [2][4] Group 2: Production and Technology - NurExone's exosomes are produced from a proprietary master cell bank, ensuring high-performance and reproducibility essential for clinical translation and future patient use [3] - The exosomes are enriched with microRNAs that support key healing tasks, as confirmed by a comprehensive analysis performed by TAmiRNA, an ISO13485-certified molecular-diagnostics laboratory [2][7] Group 3: Market Potential and Strategy - The company is focused on developing regenerative exosome-based therapies for central nervous system injuries, with its lead product, ExoPTEN, showing strong preclinical data for treating acute spinal cord and optic nerve injuries, both of which are multi-billion-dollar markets [8] - ExoTOP is expected to generate multiple revenue streams and provide high-performance exosomes to partners across regenerative medicine as production scales in the U.S. [2][8]

Core Insights - An independent study indicates that exosomes produced by NurExone Biologic Inc. outperform a recognized commercial industry standard in nerve repair, wound healing, immune system modulation, and tissue rebuilding [1][6] - The exosomes are expected to have significant applications in both therapeutic and aesthetic markets, with a focus on regenerative medicine [1][6] Group 1: Exosome Performance - NurExone's exosomes exhibit approximately 1.8-fold higher neurological potential, nearly double the anti-inflammatory activity, and a two-fold increase in tissue-regeneration and wound-healing signals compared to commercial benchmarks [4] - The exosomes are enriched with microRNAs that support key healing tasks, confirming their therapeutic potential [2][4] Group 2: Production and Scalability - The exosomes are produced from a proprietary master cell bank, ensuring high performance and reproducibility across production batches, which is crucial for clinical applications [3] - The U.S. subsidiary, ExoTOP Inc., is set to scale production using a patent-pending 3D process, which is expected to generate multiple revenue streams [2][8] Group 3: Market Potential - NurExone's lead product, ExoPTEN, has shown strong preclinical data for treating acute spinal cord and optic nerve injuries, which are multi-billion-dollar markets [8] - The company aims to provide solutions for other indications through minimally invasive targeted delivery systems, enhancing its market presence in regenerative medicine [8]

Core Insights - Adia Nutrition Inc. has announced that its healthcare clinic, Adia Med, has been approved as a provider with UnitedHealthcare, effective August 1, 2025, allowing access to the $5.3 trillion U.S. healthcare market [1][4]. Company Overview - Adia Nutrition Inc. operates in two main divisions: a supplement division offering premium organic supplements and a medical division focused on advanced stem cell therapies, including Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) [7]. Market Positioning - The integration of Adia Med into UnitedHealthcare's network enhances its ability to provide innovative, minimally invasive therapies for conditions such as joint pain, sports injuries, and chronic wounds, thereby promoting faster recovery with minimal downtime [3][4]. Commitment to Patient Care - Adia Med aims to transform patient care through regenerative solutions, ensuring that patients can efficiently resume active lifestyles while addressing chronic conditions [3][4]. Strategic Partnerships - The company encourages clinic owners and healthcare practitioners to license the Adia Med name or integrate its regenerative therapies into their practices, highlighting a focus on strategic partnerships to expand access to advanced stem cell solutions [6].

Core Viewpoint - Sanuwave Health, Inc. is set to present at the 45th Annual Canaccord Genuity Growth Conference, highlighting its position as a leading provider of next-generation, FDA-approved wound care products [1][2]. Company Overview - Sanuwave Health focuses on the research, development, and commercialization of patented, non-invasive medical systems aimed at repairing and regenerating skin, musculoskeletal tissue, and vascular structures [3]. - The company offers an end-to-end wound care portfolio that includes regenerative medicine products designed to restore the body's normal healing processes [4]. Conference Details - The group presentation is scheduled for August 13, 2025, from 9:30 to 9:55 a.m. ET, with opportunities for one-on-one meetings with investors available throughout the conference [2].

Core Insights - Adia Nutrition Inc. has partnered with CareCredit to offer financing options up to $25,000 for patient treatments, enhancing accessibility to advanced therapies in the $48.35 billion U.S. healthcare finance solutions market [1][3][4] Company Overview - Adia Nutrition Inc. is focused on regenerative medicine and personalized wellness solutions, with two main divisions: a supplement division providing premium organic supplements and a medical division specializing in advanced stem cell therapies [6] Financing Details - The partnership with CareCredit allows patients to finance treatments, including stem cell therapies, making them more attainable without financial strain [3][4] - CareCredit's financing limit of $25,000 provides greater flexibility compared to previous options, streamlining access to Adia's full range of services [4] Patient Accessibility - Patients can learn about eligibility and application for CareCredit financing through Adia Nutrition's website, which emphasizes a patient-centered approach with straightforward application processes and flexible repayment terms [5]

Core Insights - Sanuwave Health, Inc. reported preliminary revenues of $10.1 million to $10.2 million for Q2 2025, marking the highest quarterly revenues in the company's history [1][2] - The revenue for Q2 2025 reflects an increase of 41% to 42% compared to Q2 2024, while the first half of 2025 saw a revenue increase of 50% to 51% compared to the first half of 2024 [1][2] Company Developments - The CEO highlighted that the first half of 2025 has been a transition period for the company, with the addition of a new head of sales and a new head of commercial operations [3] - The company is expanding its sales team, reaching 13 salespeople and covering all national sales territories for the first time under the current CEO [3] - A national accounts manager has been added to pursue larger market opportunities, indicating a strategic focus on growth [3] Future Outlook - The company plans to release full Q2 results around August 8, 2025, providing a more comprehensive update on performance and future plans [3] - Sanuwave is focused on the research, development, and commercialization of patented, non-invasive medical systems aimed at tissue repair and regeneration [4] - The company's portfolio includes regenerative medicine products that support normal healing processes across various medical conditions [5]

Core Insights - Longeveron Inc. has appointed Than Powell as Chief Business Officer to lead its business strategy and international efforts, particularly in Alzheimer's disease and hypoplastic left heart syndrome (HLHS) programs [1][2][4] - The company has recently completed enrollment for its pivotal Phase 2 trial of laromestorcel for HLHS, with top-line data expected in approximately 13 months, which could support the first Biological License Application (BLA) submission [2][6] Company Overview - Longeveron is a clinical stage biotechnology company focused on developing regenerative medicines for life-threatening and chronic aging-related conditions [6] - The lead investigational product, laromestrocel (Lomecel-B™), is an allogeneic mesenchymal stem cell therapy derived from young, healthy adult donors, with potential applications across various disease areas [6] - The company is pursuing three pipeline indications: HLHS, Alzheimer's disease, and aging-related frailty, and has received multiple FDA designations for its programs [6] Leadership Background - Than Powell brings over 25 years of experience in the pharmaceutical and biotech industries, having held leadership roles at organizations such as GSK and Eli Lilly [4][5] - Prior to joining Longeveron, Powell led Corporate Development & Strategy for Surescripts, culminating in the company's acquisition by TPG [4]

Company Overview - BioStem Technologies is a leading MedTech company focused on improving the lives of patients with chronic, non-healing wounds through innovative solutions [3][14] - The company develops and manufactures placental-derived allografts using proprietary BioREtain® technology, which preserves tissue's native properties and optimizes clinical outcomes [3][15] - BioStem's products are used by clinicians nationwide to address the growing demand for advanced wound care solutions [3][14] Leadership Recognition - Jason Matuszewski, CEO and Chairman of BioStem Technologies, was awarded the Entrepreneur Of The Year 2025 Florida Award by Ernst & Young LLP [1][4] - The award recognizes leaders who demonstrate long-term value creation, entrepreneurial spirit, and significant growth and impact [2][5] - Matuszewski emphasized the collective effort of the BioStem team in achieving this recognition, highlighting their commitment to innovation and patient care [3][4] Future Aspirations - As a Florida award winner, Matuszewski is eligible for the Entrepreneur Of The Year 2025 National Awards, with winners announced in November [4] - The National Award winner will compete for the EY World Entrepreneur Of The Year™ Award in June 2026 [4][8] - BioStem aims to expand its impact and continue advancing its platform in the healthcare system [3][14]

TORONTO and HAIFA, Israel, May 30, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce that Professor Nahshon Knoller M.D., senior clinical advisor to the Company, will be presenting at the prestigious annual meeting of the American Spinal Injury Association (“ASIA”), where he will discuss the Company’s plans for future clinical trials in 2026 in the field of acute spinal cord injuries (“SCI”) for ExoPTEN, a first-in-clas ...

Core Insights - Sanuwave Health, Inc. has appointed Greg Bazar to its Board of Directors, bringing extensive experience in engineering, technology, and cybersecurity [1][2][3] - Bazar's background includes founding Simpatico Systems and significant roles at 3D-P and Caterpillar, indicating a strong leadership and innovation track record [2][3] - The company emphasizes interdisciplinary expertise as crucial for its future growth and innovation in wound care technology [3] Company Overview - Sanuwave Health focuses on the research, development, and commercialization of patented, non-invasive medical systems aimed at repairing and regenerating skin, musculoskeletal tissue, and vascular structures [5] - The company's portfolio includes regenerative medicine products that support the body's natural healing processes across various medical conditions [6] Board Changes - Long-time board member Michael Stolarski is stepping down to focus on personal interests but will remain as a consultant to ensure continuity during the transition [4]